GLP-1 MEDICATIONS · PERIMENOPAUSE
Blood Tests for Women on GLP-1 Drugs During Perimenopause
Women aged 40–64 are the fastest-growing group of GLP-1 users in the UK. Many of these women are also navigating perimenopause — a hormonal transition that fundamentally changes how the body handles metabolism, bone density, thyroid function, and cardiovascular risk. Standard GLP-1 monitoring panels miss half the picture because they ignore the hormonal upheaval happening underneath.
This guide covers the blood tests that matter specifically for perimenopausal women on Ozempic (semaglutide), Wegovy, or Mounjaro (tirzepatide) — the risks that compound when both are happening at once, and the biomarkers that let you stay ahead of problems your GP may not flag.
Why perimenopause changes everything about GLP-1 monitoring
Standard GLP-1 monitoring focuses on liver function, kidney function, HbA1c, and lipids. That's adequate for a 35-year-old man losing weight. It is not adequate for a 48-year-old woman whose oestrogen is already declining, whose bone density is already shifting, and whose thyroid function is already under strain from hormonal changes.
Perimenopause typically begins in the mid-40s and lasts 4–10 years. During this time, oestrogen and progesterone levels fluctuate wildly before their final decline. This isn't just about hot flushes and irregular periods — oestrogen is a master regulator of bone metabolism, cardiovascular protection, insulin sensitivity, thyroid function, and body composition.
When you add a GLP-1 drug that causes rapid weight loss, reduced food intake, and shifts in metabolic hormones, you create a set of compounded risks that don't exist for younger patients or for perimenopausal women not on weight-loss medication. The only way to monitor these risks is through blood tests that go beyond the standard panel.
A 2025 review in Current Opinion in Obstetrics and Gynecology specifically noted that GLP-1 prescribers “need to consider the unique risks of this population, including accelerated bone loss and lean mass depletion” — yet most monitoring protocols don't include a single bone or hormone marker.
The four “double hit” risks you need to know
Each of these risks exists independently in perimenopause and independently on GLP-1 drugs. When both are happening at once, the effects compound. Blood tests are how you detect the problem before it becomes clinical.
1. Bone density loss
WHY THE RISK IS COMPOUNDED
Perimenopause accelerates bone resorption as oestrogen declines. GLP-1 drugs cause additional bone loss through rapid weight reduction — mechanical unloading removes the stimulus that keeps bones dense. Together, this is a double hit on both the hormonal and mechanical pathways that protect your skeleton.
THE EVIDENCE
A 2024 study in JAMA Network Open found that GLP-1 treatment alone reduced hip bone mineral density by 2.6% and lumbar spine by 2.1% over 52 weeks. Importantly, exercise combined with GLP-1 preserved bone — the drug alone did not. For perimenopausal women already losing 1-2% bone density per year from oestrogen decline, the combined annual loss can approach 4-5%.
HOW TO MONITOR
Bone turnover markers (CTX for resorption, P1NP for formation) in blood tests detect changes 6-12 months before a DEXA scan would. Vitamin D and calcium levels tell you whether the building blocks are even available.
2. Muscle mass depletion
WHY THE RISK IS COMPOUNDED
Perimenopause brings natural sarcopenia — loss of muscle mass and strength accelerated by declining oestrogen and testosterone. GLP-1 drugs cause 15-40% of total weight lost to come from lean mass rather than fat. The combination means a perimenopausal woman can lose muscle from both directions simultaneously.
THE EVIDENCE
A 2024 review in Diabetes, Obesity and Metabolism reported that lean mass can account for a substantial proportion of weight lost on GLP-1 therapies. For perimenopausal women, who are already experiencing age-related muscle decline, this creates a compounding trajectory toward sarcopenia — the point where reduced muscle mass begins to impair daily function.
HOW TO MONITOR
Track testosterone, DHEA-S, and SHBG. Rising SHBG (common during weight loss) binds free testosterone, reducing the amount available for muscle protein synthesis. A dropping testosterone alongside rising SHBG is a warning signal.
3. Thyroid disruption
WHY THE RISK IS COMPOUNDED
Perimenopause commonly disrupts thyroid function — the two are tightly linked through shared hormonal pathways. GLP-1 drugs carry an MHRA/FDA black box warning regarding medullary thyroid carcinoma (from rodent studies), and rapid weight loss itself changes thyroid hormone requirements. Women on levothyroxine may need dose adjustments every 3-6 months during active weight loss.
THE EVIDENCE
A large retrospective study published in Diabetes Care (2025) found a hazard ratio of 1.58 for all thyroid cancer with 1-3 years of GLP-1 use — though causation remains debated and absolute risk is low. The more practical concern is subclinical thyroid dysfunction: perimenopause can mask hypothyroid symptoms (fatigue, weight gain, brain fog overlap with both conditions), and GLP-1-driven weight loss can unmask or worsen existing thyroid issues.
HOW TO MONITOR
TSH and Free T4 every 6 months. If you're on levothyroxine, test 6-8 weeks after any significant weight change (>5 kg). Symptoms alone are unreliable — blood tests are the only way to distinguish thyroid dysfunction from perimenopause symptoms.
4. Gallbladder disease
WHY THE RISK IS COMPOUNDED
Women over 40 are already at elevated risk for gallstones — oestrogen increases bile cholesterol saturation. Rapid weight loss (more than 1.5 kg per week) is an independent gallstone risk factor. GLP-1 drugs at weight-loss doses significantly increase gallbladder and biliary disease risk.
THE EVIDENCE
A meta-analysis of 76 randomised controlled trials (n=103,371) published in JAMA Internal Medicine found that GLP-1 drugs increased the risk of gallbladder and biliary diseases by 37% overall — and by 129% at the higher doses used for weight management. Perimenopausal women are already in the highest-risk demographic for gallstones. The combination of rapid weight loss, hormonal changes, and GLP-1 effects creates a triple risk factor.
HOW TO MONITOR
This is primarily a clinical risk rather than a blood-test risk. However, liver function tests (ALT, GGT) can flag biliary obstruction early. Report any severe upper abdominal pain, especially after meals, to your GP immediately.
Reproductive hormones — tracking the transition
You can't manage what you can't measure. These markers tell you where you are in the perimenopausal transition and how GLP-1 treatment is affecting your hormonal environment.
FSH (Follicle-Stimulating Hormone) →
WHY IT MATTERS
FSH is the primary marker for confirming perimenopause. As ovarian function declines, FSH rises — your brain is sending stronger signals to ovaries that are responding less. GLP-1 drugs don't directly alter FSH, but significant fat loss reduces peripheral oestrogen production (adipose tissue converts androgens to oestrogen via aromatase), which can push FSH higher and accelerate the 'felt' hormonal decline.
WHAT TO WATCH
FSH below 10 IU/L is typically premenopausal. Between 10-25 IU/L suggests early perimenopause. Above 25 IU/L indicates established perimenopause. Above 40 IU/L with 12 months of no periods confirms menopause. Note: FSH fluctuates significantly in perimenopause — a single reading is less informative than the trend over 6-12 months.
HOW OFTEN TO TEST
Baseline, then every 6 months. Always test on day 2-5 of your cycle if you're still having periods.
Oestradiol (E2) →
WHY IT MATTERS
Oestradiol is the primary form of oestrogen. In perimenopause it fluctuates wildly — sometimes higher than premenopausal levels, sometimes crashing to postmenopausal levels within the same cycle. Tracking oestradiol alongside FSH helps your doctor assess whether you'd benefit from HRT, and provides a baseline if you're considering combining HRT with GLP-1 treatment.
WHAT TO WATCH
Premenopausal: 70-500 pmol/L depending on cycle phase. Postmenopausal: below 100 pmol/L. In perimenopause, expect erratic readings — the trend over multiple tests matters more than any single value. Persistently low oestradiol with high FSH suggests you're approaching menopause.
HOW OFTEN TO TEST
Baseline, then every 6 months (same timing as FSH — day 2-5 of cycle if applicable).
SHBG (Sex Hormone-Binding Globulin) →
WHY IT MATTERS
SHBG binds testosterone and oestradiol, making them unavailable to tissues. Weight loss increases SHBG — this is normally a positive metabolic signal. But in perimenopause, rising SHBG can bind the already-declining free oestradiol and testosterone, potentially worsening symptoms like fatigue, low mood, brain fog, and reduced muscle recovery.
WHAT TO WATCH
Normal range is 18-144 nmol/L in women. The key is the trend: if SHBG is rising rapidly during GLP-1 weight loss while your oestradiol is already declining, the combined effect on free hormone levels may be clinically significant — even if each individual marker looks 'normal' in isolation.
HOW OFTEN TO TEST
Baseline, then every 6 months.
Testosterone →
WHY IT MATTERS
Testosterone isn't just a male hormone — it's critical for women's muscle mass, bone density, energy, mood, and libido. Perimenopause brings a gradual decline in ovarian testosterone production, and weight loss increases SHBG which binds what's left. Monitoring testosterone helps explain symptoms like persistent fatigue and muscle weakness that might otherwise be blamed on 'just perimenopause.'
WHAT TO WATCH
Total testosterone in women: 0.5-2.4 nmol/L. Below 0.5 nmol/L with symptoms may warrant discussion about testosterone replacement (now included in some HRT prescriptions via the British Menopause Society guidelines). If testosterone drops during GLP-1 treatment alongside rising SHBG, the free testosterone available to tissues may be inadequate.
HOW OFTEN TO TEST
Baseline, then every 6 months.
Bone health — the risk no one talks about
This is the most important section of this guide. Bone density loss is the least-discussed and potentially most consequential risk for perimenopausal women on GLP-1 drugs. A 2024 study in JAMA Network Open found that GLP-1 treatment without exercise reduced hip and spine bone mineral density significantly — while exercise combined with GLP-1 treatment preserved bone.
The problem is that DEXA scans (the standard bone density test) only detect changes after they've happened — often 12–24 months after bone loss accelerates. Blood markers of bone turnover detect the change 6–12 months earlier, giving you time to intervene with exercise, calcium, vitamin D, and potentially HRT before irreversible loss occurs.
CTX (C-terminal telopeptide) — bone resorption marker
WHY IT MATTERS
CTX measures the rate at which your body is breaking down bone. In perimenopause, declining oestrogen removes the brake on osteoclast activity (the cells that dissolve bone). GLP-1 weight loss adds mechanical unloading and caloric deficit. A rising CTX tells you bone resorption is accelerating before your DEXA shows any change.
WHAT TO WATCH
Premenopausal women: CTX below 0.30 μg/L is typical. Early postmenopausal: 0.30–0.55 μg/L. If your CTX rises above 0.55 μg/L while on GLP-1 treatment, discuss with your GP whether bone-protective interventions (exercise, HRT, vitamin D optimisation) are sufficient or whether a DEXA scan is warranted.
HOW OFTEN TO TEST
Baseline, then every 6 months. Always test fasting in the morning — CTX has a diurnal rhythm (highest before breakfast).
Vitamin D →
WHY IT MATTERS
Vitamin D is essential for calcium absorption and bone mineralisation. In the UK, most adults are deficient between October and March. GLP-1 drugs reduce food intake — including the small amount of dietary vitamin D you'd normally get. For perimenopausal women whose bones are already under stress, vitamin D deficiency turns a managed risk into an accelerating one.
WHAT TO WATCH
Below 25 nmol/L is deficient. 25-50 nmol/L is insufficient. 50-125 nmol/L is optimal. Most UK adults in winter are below 50. If you're on GLP-1 treatment and perimenopausal, aim for the higher end of optimal (75-100 nmol/L). Supplementation of 1,000-4,000 IU daily may be needed — guided by your blood levels.
HOW OFTEN TO TEST
Baseline, then every 6 months. Test in autumn (October) and spring (March) to capture seasonal variation.
Thyroid function — two reasons to watch it closely
Thyroid monitoring matters doubly for perimenopausal women on GLP-1 drugs. First, the MHRA and FDA black box warning regarding medullary thyroid carcinoma means anyone on GLP-1 medication should have thyroid surveillance. Second, perimenopause independently disrupts thyroid function — approximately 1 in 8 women develop thyroid dysfunction during the menopausal transition.
The symptom overlap is treacherous. Fatigue, weight gain, brain fog, mood changes, and cold sensitivity are symptoms of both hypothyroidism and perimenopause. Without a blood test, you can't tell which is causing what — and a missed thyroid diagnosis means months or years of unnecessary suffering from a treatable condition.
Thyroid (TSH) →
WHY IT MATTERS
TSH is the first-line thyroid screen. In perimenopause, fluctuating oestrogen affects thyroid-binding globulin, which can transiently alter TSH even when the thyroid itself is healthy. GLP-1 weight loss additionally changes thyroid hormone requirements. If you're on levothyroxine, rapid weight loss may mean your current dose becomes too high — potentially causing anxiety, palpitations, and further bone loss.
WHAT TO WATCH
Normal range: 0.4-4.0 mU/L. Optimal for most women: 1.0-2.5 mU/L. If TSH is above 4.0, request Free T4. If TSH is below 0.4, especially with symptoms (tremor, rapid heartbeat, anxiety), seek medical review. On levothyroxine: retest 6-8 weeks after any weight change greater than 5 kg.
HOW OFTEN TO TEST
Baseline, then every 6 months. More frequently if on thyroid medication.
Metabolic markers — tracking real progress
GLP-1 drugs and perimenopause push insulin sensitivity in opposite directions. GLP-1 drugs improve it; declining oestrogen worsens it. The net effect is usually positive, but tracking these markers tells you whether the drug is genuinely improving your metabolic health or just changing the number on the scale.
HbA1c →
WHY IT MATTERS
HbA1c reflects your average blood sugar over the previous 2-3 months. Perimenopause worsens insulin resistance through declining oestrogen — even lean, active women can see their HbA1c creep up. GLP-1 drugs are powerful glucose-lowering agents. Tracking HbA1c confirms the drug is delivering metabolic benefit, not just weight loss.
WHAT TO WATCH
Below 42 mmol/mol (6.0%): normal. 42-47 mmol/mol (6.0-6.4%): prediabetic range. Above 48 mmol/mol (6.5%): diabetic range. Most women on GLP-1 treatment see HbA1c improve by 5-10 mmol/mol within 3-6 months.
HOW OFTEN TO TEST
Baseline, then every 3-6 months.
Cholesterol & ApoB →
WHY IT MATTERS
Oestrogen is cardioprotective — it keeps HDL high and LDL low. As oestrogen declines in perimenopause, LDL often rises and HDL drops, increasing cardiovascular risk. GLP-1 drugs improve the lipid profile through weight loss and direct metabolic effects. ApoB is the single best predictor of cardiovascular risk — more accurate than LDL alone.
WHAT TO WATCH
ApoB below 1.0 g/L is generally desirable; below 0.8 g/L is optimal. Total cholesterol: aim for below 5.0 mmol/L. LDL below 3.0 mmol/L. Track the trend — if your ApoB is rising despite weight loss, it may signal that oestrogen decline is outpacing the metabolic benefit of the drug.
HOW OFTEN TO TEST
Baseline, then every 6 months.
hs-CRP (High-Sensitivity C-Reactive Protein) →
WHY IT MATTERS
hs-CRP measures systemic inflammation. Adipose tissue is a major source of chronic inflammation, and GLP-1 weight loss typically reduces hs-CRP significantly. But perimenopause can independently increase inflammation through oestrogen fluctuations and disrupted sleep. Tracking hs-CRP tells you whether the net inflammatory trend is improving.
WHAT TO WATCH
Below 1.0 mg/L: low cardiovascular risk. 1.0-3.0 mg/L: moderate. Above 3.0 mg/L: high (excluding acute infection). A single elevated reading after a cold or illness is meaningless — always retest if unexpectedly high.
HOW OFTEN TO TEST
Baseline, then every 6 months.
Muscle mass and body composition
A 2024 review in Diabetes, Obesity and Metabolism confirmed that lean mass loss on GLP-1 drugs is a significant concern. For perimenopausal women, muscle loss is already accelerating due to declining anabolic hormones. The best defence is resistance training (3–4 sessions per week) and high protein intake (1.2–1.6 g per kg of body weight daily).
Blood tests can't measure muscle directly, but they can flag the hormonal environment that determines whether you're preserving or losing lean mass.
DHEA-S →
WHY IT MATTERS
DHEA-S is the most abundant steroid hormone in your body and a precursor to both testosterone and oestrogen. It declines steadily with age, and the rate of decline accelerates in perimenopause. Rapid weight loss and caloric restriction can further suppress DHEA-S through adrenal stress. Falling DHEA-S alongside falling testosterone is a signal that your body's anabolic capacity is declining — you may need to increase protein intake and adjust exercise intensity.
WHAT TO WATCH
DHEA-S varies widely by age. For women 40-49: typical range is 2.0-9.5 µmol/L. For women 50-59: 1.0-7.0 µmol/L. The trend matters more than any single reading — a drop of more than 30% from your baseline warrants attention.
HOW OFTEN TO TEST
Baseline, then every 6 months.
Nutritional deficiencies — the hidden cost of eating less
GLP-1 drugs work partly by reducing appetite — which is the point. But eating less also means absorbing fewer micronutrients. Nausea and GI side effects compound this further. For perimenopausal women, specific deficiencies carry outsized consequences.
Ferritin →
WHY IT MATTERS
Ferritin reflects your body's iron stores. Perimenopausal women with heavy or irregular periods are already at high risk of iron depletion. Adding GLP-1-driven reduced food intake can tip borderline stores into deficiency — causing fatigue, brain fog, and poor exercise recovery that gets blamed on 'the menopause' rather than a treatable deficiency.
WHAT TO WATCH
Below 30 µg/L: depleted (even if your GP says 'normal' — the NHS lower threshold of 15 is far too low for optimal function). 30-100 µg/L: adequate. Above 100 µg/L with regular periods: investigate further. If you're losing weight on GLP-1s and still having periods, ferritin below 50 warrants iron supplementation.
HOW OFTEN TO TEST
Baseline, then every 3-6 months if menstruating. Every 6 months if periods have stopped.
Vitamin B12 →
WHY IT MATTERS
B12 deficiency causes fatigue, neurological symptoms, and cognitive changes — all of which mimic perimenopause. GLP-1 drugs reduce dietary intake and can alter gut absorption. Women over 40 already have declining B12 absorption due to reduced stomach acid. If you're also taking PPIs (proton pump inhibitors for acid reflux — common with GLP-1 GI side effects), B12 absorption drops further.
WHAT TO WATCH
Below 200 pg/mL: deficient. 200-300 pg/mL: borderline (symptoms common in this range despite being 'normal'). Above 300 pg/mL: adequate. Active B12 (holotranscobalamin) is a more sensitive early marker if available.
HOW OFTEN TO TEST
Baseline, then every 6 months.
Folate →
WHY IT MATTERS
Folate works alongside B12 in methylation pathways that affect mood, energy, and cardiovascular health. Reduced food intake on GLP-1 treatment can deplete folate stores. Low folate alongside rising homocysteine is a cardiovascular risk signal.
WHAT TO WATCH
Below 3.0 µg/L: deficient. Above 3.0 µg/L: adequate. Optimal: above 5.0 µg/L.
HOW OFTEN TO TEST
Baseline, then every 6 months.
Magnesium →
WHY IT MATTERS
Magnesium is involved in over 300 enzymatic reactions including bone formation, muscle function, sleep quality, and blood sugar regulation — all areas under pressure during perimenopause and GLP-1 treatment. Most UK adults don't get enough through diet, and GLP-1-driven food reduction makes this worse. Low magnesium can worsen sleep disruption, muscle cramps, and anxiety — common perimenopause complaints.
WHAT TO WATCH
0.7-1.0 mmol/L is the normal serum range. Below 0.7 mmol/L is clinically low. Note: serum magnesium is a poor marker of total body magnesium (only 1% of magnesium is in blood). If you have symptoms of deficiency (muscle cramps, poor sleep, anxiety) despite normal serum levels, a trial of supplementation (200-400 mg daily) is reasonable.
HOW OFTEN TO TEST
Baseline, then every 6 months.
GLP-1 drugs and HRT — what the evidence says
This is one of the most common questions women ask, and the evidence is reassuring. The British Menopause Society confirms that GLP-1 drugs and HRT can be used together safely. In fact, there's evidence the combination may be synergistic.
A 2024 study published in Menopause (Hurtado et al.) found that postmenopausal women on HRT plus semaglutide lost 16% of their body weight at 12 months, compared with 12% on semaglutide alone (p=0.04). Oestrogen appears to enhance GLP-1 receptor signalling — the two systems converge on similar metabolic pathways in the liver, brain, and adipose tissue.
HRT also directly addresses several of the compounded risks outlined above:
- Bone protection: HRT is one of the most effective interventions for preventing perimenopausal bone loss — potentially counteracting the bone loss caused by GLP-1 weight loss
- Muscle preservation: Oestrogen replacement supports muscle protein synthesis and recovery
- Cardiovascular protection: HRT started within 10 years of menopause onset reduces cardiovascular risk
- Insulin sensitivity: Oestrogen replacement improves insulin sensitivity — working in the same direction as the GLP-1 drug
One practical consideration: GLP-1 drugs slow gastric emptying, which can reduce absorption of oral medications — including oral HRT. If you're on GLP-1 treatment, transdermal oestrogen (patches, gels, or sprays) may be more reliable than oral forms. Discuss this with your prescriber.
Blood tests help guide HRT decisions: FSH and oestradiol confirm your menopausal status, testosterone can indicate whether testosterone replacement would help, and a full panel rules out contraindications. If you're considering combining GLP-1 and HRT, a baseline blood test before starting the second medication is essential.
Your testing schedule
This table shows what to test and when. Baseline means before or within the first 2 weeks of starting GLP-1 treatment.
| BIOMARKER | BASELINE | 3 MONTHS | 6 MONTHS | ONGOING |
|---|---|---|---|---|
| FSH & Oestradiol | Yes | — | Yes | Every 6 months |
| SHBG & Testosterone | Yes | — | Yes | Every 6 months |
| CTX (bone resorption) | Yes | — | Yes | Every 6 months |
| Vitamin D | Yes | Yes | Yes | Every 6 months |
| Thyroid (TSH, Free T4) | Yes | — | Yes | Every 6 months |
| HbA1c | Yes | Yes | Yes | Every 3–6 months |
| ApoB & Lipids | Yes | — | Yes | Every 6 months |
| hs-CRP | Yes | — | Yes | Every 6 months |
| Liver function (ALT, GGT) | Yes | Yes | Yes | Every 6 months |
| Kidney (creatinine, eGFR) | Yes | Yes | Yes | Every 6 months |
| Ferritin, B12, folate | Yes | Yes | Yes | Every 6 months |
| DHEA-S | Yes | — | Yes | Every 6 months |
| Magnesium | Yes | — | Yes | Every 6 months |
Timing tip: If you're still having periods, test FSH and oestradiol on day 2–5 of your cycle. Test CTX fasting before 10am. All other markers can be tested at any time, though a 10–12 hour fast gives the cleanest lipid and glucose readings.
What your GP probably won’t check
GPs work within time-constrained appointments and protocol-driven testing. If you're on a GLP-1 drug through the NHS, your GP will likely check liver function, kidney function, HbA1c, and possibly thyroid. If you're on a private prescription through a weight-loss clinic, many clinics check even less.
Here's what falls through the cracks for perimenopausal women:
- Bone turnover markers (CTX) — rarely requested outside specialist osteoporosis clinics, yet they detect accelerated bone loss months before a DEXA scan
- SHBG — almost never included in routine panels, yet it determines how much of your remaining oestrogen and testosterone is actually available to your tissues
- ApoB — the best single predictor of cardiovascular risk, but most GPs still rely on total cholesterol and LDL
- DHEA-S — not part of standard perimenopause assessment, but reveals adrenal hormone reserve and anabolic capacity
- hs-CRP — rarely tested in the context of weight loss, yet it's one of the clearest markers of whether cardiovascular risk is actually improving
- Magnesium — almost never tested despite widespread deficiency and its role in bone health, sleep, and muscle function
This isn't a criticism of GPs — it's a reflection of how the system works. A 10-minute appointment following NICE guidelines for GLP-1 prescribing simply doesn't have room for the broader picture. Private blood testing fills that gap.
Frequently asked questions
Can I take Ozempic or Wegovy and HRT at the same time?
Yes. The British Menopause Society confirms GLP-1 drugs and HRT can be used concurrently. Evidence suggests the combination may even be synergistic — a 2024 study found women on HRT plus semaglutide lost 16% body weight at 12 months versus 12% on semaglutide alone. One practical note: GLP-1 drugs slow gastric emptying, so transdermal HRT (patches, gels, sprays) may be more reliably absorbed than oral forms.
Do GLP-1 drugs cause bone loss?
Research suggests they can. A 2024 JAMA Network Open study found GLP-1 treatment without exercise reduced hip BMD by 2.6% and spine BMD by 2.1% over 52 weeks. The good news: exercise combined with GLP-1 treatment preserved bone density. For perimenopausal women already experiencing oestrogen-driven bone loss, resistance training and weight-bearing exercise are essential while on GLP-1 medication.
Will Ozempic affect my menopause symptoms?
GLP-1 drugs don't directly alter oestrogen or FSH. However, significant fat loss reduces peripheral oestrogen production (adipose tissue converts androgens to oestrogen). This can make the hormonal decline of perimenopause feel more abrupt. On the other hand, weight loss often improves sleep, energy, and joint pain. Blood tests help you track whether the hormonal changes are clinically significant.
Can GLP-1 drugs cause early menopause?
There is no evidence that GLP-1 drugs cause premature ovarian insufficiency or accelerate the timing of menopause. However, rapid fat loss can reduce peripheral oestrogen production, potentially making perimenopausal symptoms feel worse or appear sooner than they otherwise would. This is a change in symptoms, not a change in underlying ovarian function.
How often should I get blood tests while on GLP-1 medication during perimenopause?
Get a comprehensive baseline before starting, then at 3 months, 6 months, and every 6 months thereafter. The 3-month test catches early nutritional deficiencies and metabolic changes. The 6-month test is when hormone shifts and bone marker changes become detectable. Continue testing every 6 months for as long as you're on the medication.
Should I check my thyroid on Ozempic during perimenopause?
Absolutely. You have two independent reasons: the MHRA/FDA thyroid safety monitoring for GLP-1 drugs, and the increased risk of thyroid dysfunction during perimenopause. Symptoms of hypothyroidism (fatigue, weight gain, brain fog) overlap almost completely with perimenopause symptoms. A simple TSH blood test every 6 months rules it out or catches it early.
How do I prevent muscle loss on GLP-1 drugs during perimenopause?
Three evidence-based strategies: (1) resistance training 3-4 times per week, (2) protein intake of 1.2–1.6 g per kg of body weight daily, and (3) monitor testosterone, DHEA-S, and SHBG to ensure your hormonal environment supports muscle preservation. If these markers are declining, discuss testosterone replacement with your prescriber — it's increasingly prescribed alongside HRT for perimenopausal women.
Can Ozempic cause gallbladder problems in perimenopausal women?
Yes, and perimenopausal women are in the highest-risk group. A meta-analysis of 76 trials found GLP-1 drugs at weight-loss doses more than doubled gallbladder disease risk. Women over 40 are already at elevated risk due to hormonal changes. Report any severe upper abdominal pain (especially after meals) to your GP immediately. Losing weight gradually rather than rapidly reduces the risk.
Get the full picture while on GLP-1 medication
Our Performance panel covers metabolic, hormonal, thyroid, nutritional, and inflammatory markers in a single home blood test. Results in 5 days, reviewed by a GMC-registered doctor.
Related guides
Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. GLP-1 receptor agonists and hormone replacement therapy are prescription medications — always follow your prescriber's guidance regarding monitoring and dosage. Do not start, stop, or change the dosage of any medication based on information in this article without consulting your doctor. Perimenopause symptoms and timing vary significantly between individuals. If you experience severe side effects (persistent vomiting, severe abdominal pain, signs of pancreatitis), seek medical attention immediately. All Helvy blood tests are processed by UKAS-accredited NHS laboratories and reviewed by a GMC-registered doctor.
Last updated: April 2026 · By Helvy · Medically reviewed by a GMC-registered doctor